Mark Bagarazzi, MD

Dr. Bagarazzi has spent more than 30 years developing vaccines for infectious disease and cancer. He is currently a senior program officer in the Global Health division of the Gates Foundation. He previously worked to develop the next generation of cancer vaccines as chief medical officer of NEUVOGEN. He also led the development of both prophylactic and therapeutic vaccines and their investigational medical device as chief medical officer of Inovio Pharmaceuticals from 2010 to 2019. Prior to Inovio, Dr. Bagarazzi was director of Worldwide Regulatory Affairs for vaccines and biologics at Merck. Dr. Bagarazzi led ongoing vaccine product and regulatory development of Merck’s ZOSTAVAX®, the leading vaccine for shingles. He successfully led the regulatory process through to FDA approval of RotaTeq®, Merck’s vaccine against rotavirus and was later responsible for global regulatory activities related to Merck vaccine candidates for the prevention of HIV/AIDS. Prior to joining Merck in 2001, he was director of the HIV/AIDS program for St. Christopher’s Hospital for Children in Philadelphia.

Dr. Bagarazzi was an assistant professor of pediatrics at Drexel College of Medicine and a guest lecturer on vaccines and immunotherapeutics at the Perelman School of Medicine at the University of Pennsylvania. He was board certified in pediatrics and pediatric infectious diseases after completing a fellowship in pediatric infectious diseases at the Children’s Hospital of Philadelphia. He holds a BS in electrical engineering magna cum laude from New Jersey Institute of Technology and received his MD degree with honors from what is now known as Rutgers New Jersey Medical School.